(Yicai Global) Aug. 10 -- BGI Genomics Co. [SHE:300676] is still the Shenzhen Stock Exchange's most sought-after stock since its initial public offering, having hit limit up for 19 straight trading days.

Daily fluctuations in A-share stock prices are capped at plus or minus 10 percent. BGI's share price closed at CNY109.18 (USD16.35) yesterday, a more than 700 percent increase from its CNY13.64 issuing price.

After an impressive streak lasting several weeks, some investors looked to cash early yesterday morning, but the price bounced back and hit the limit up just 30 minutes later.

Marked cap reached nearly CNY43.7 billion (USD6.54 billion) giving a price-to-earnings ratio of 115. The firm's turnover rate has stayed at less than 2 percent, suggesting few investors have sold any stock over the past 19 trading days.

The stock has been well received since its IPO on July 14. Some market participants dubbed it the "Google of the biotech market" and a "unicorn in the biomedical industry." They predicted that BGI Genomics would continuously hit the upper day limit after trading began.

Several brokerages recommended the genetic sequencing company before the IPO. The most optimistic forecast, from Zhu Guoguang, an analyst at Southwest Securities [SHA:600369], projected its price range to be between CNY70.8 and CNY94.4, considerably underestimating A-share investors' confidence in the company.

Relatively conservative analysts, like Shanghai Securities' Wei Yun, valued the stock between CNY46.35 to CNY55.62.